[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event

Rhea-AI Filing Summary

Pliant Therapeutics reported an executive change: Chief Business Officer Hans Hull resigned effective October 20, 2025. The company stated the resignation was not due to any disagreement related to operations, policies, or practices. The report was signed by Keith Cummings, M.D., MBA, in his capacity as Chief Financial Officer.

0001746473FALSE00017464732025-10-202025-10-200001746473plrx:CommonStockParValue0.0001PerShareMember2025-10-202025-10-200001746473plrx:SeriesAJuniorParticipatingPreferredPurchaseRightsMember2025-10-202025-10-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________

FORM 8-K

__________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2025

__________________________________________

PLIANT THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

__________________________________________

Delaware			001-39303			47-4272481
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
331 Oyster Point Blvd., South San Francisco, CA						94080
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 481-6770

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			PLRX			The Nasdaq Stock Market LLC
Series A Junior Participating Preferred Purchase Rights			N/A			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 20, 2025, Pliant Therapeutics, Inc. (the “Company”) received and accepted the resignation of Hans Hull as Chief Business Officer of the Company, effective that same day. Mr. Hull’s resignation was not due to a disagreement on any matter related to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			PLIANT THERAPEUTICS, INC.
Date: October 24, 2025			By:			/s/ Keith Cummings
						Keith Cummings, M.D., MBA
						Chief Financial Officer

FAQ

What did PLRX disclose in this 8-K?

Pliant Therapeutics disclosed that Chief Business Officer Hans Hull resigned effective October 20, 2025.

Was Hans Hull’s resignation from PLRX due to a disagreement?

The company stated the resignation was not due to any disagreement related to operations, policies, or practices.

What is the effective date of the PLRX executive change?

The effective date is October 20, 2025.

Who signed the PLRX report?

The report was signed by Keith Cummings, M.D., MBA, Chief Financial Officer.

Which PLRX security is listed on Nasdaq?

Common Stock (par value $0.0001) is listed under ticker PLRX on The Nasdaq Stock Market LLC.

What exchange-related title was also listed for PLRX?

Series A Junior Participating Preferred Purchase Rights were also listed with The Nasdaq Stock Market LLC.